S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
OTCMKTS:BRRGF

BerGenBio ASA (BRRGF) Stock Forecast, Price & News

$1.77
0.00 (0.00%)
(As of 05/12/2023)
Compare
Today's Range
$1.77
$1.77
50-Day Range
$1.77
$1.77
52-Week Range
$1.77
$2.35
Volume
N/A
Average Volume
200 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BRRGF stock logo

About BerGenBio ASA (OTCMKTS:BRRGF) Stock

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

BRRGF Price History

BRRGF Stock News Headlines

H.C. Wainwright Reaffirms Their Buy Rating on BerGenBio AS (BRRGF)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BerGenBio AS (BRRGF) Gets a Buy from H.C. Wainwright
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BRRGF Real-Time Quotes
BRRGF Price/Earnings & PEG Ratios
See More Headlines
Receive BRRGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BerGenBio ASA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BRRGF
CIK
N/A
Fax
N/A
Employees
28
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Martin Olin (Age 54)
    Chief Exec. Officer
    Comp: $863.23k
  • Mr. Rune Skeie (Age 50)
    Chief Financial Officer
    Comp: $235.5k
  • Dr. James Barnes Ph.D.
    Chief Operating Officer
  • Ms. Gayle M. Mills M.B.A (Age 68)
    Chief Bus. Officer
  • Ms. Cristina Oliva M.D.
    Chief Medical Officer
  • Graham Morell
    Head of IR
  • Dr. Akil Jackson
    Medical Director













BRRGF Stock - Frequently Asked Questions

Should I buy or sell BerGenBio ASA stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BRRGF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BRRGF, but not buy additional shares or sell existing shares.
View BRRGF analyst ratings
or view top-rated stocks.

How have BRRGF shares performed in 2023?

BerGenBio ASA's stock was trading at $1.77 at the start of the year. Since then, BRRGF shares have increased by 0.0% and is now trading at $1.77.
View the best growth stocks for 2023 here
.

Are investors shorting BerGenBio ASA?

BerGenBio ASA saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 241,000 shares, a decrease of 90.2% from the August 15th total of 2,463,000 shares. Based on an average daily volume of 200 shares, the short-interest ratio is presently 1,205.0 days.
View BerGenBio ASA's Short Interest
.

What is BerGenBio ASA's stock symbol?

BerGenBio ASA trades on the OTCMKTS under the ticker symbol "BRRGF."

How do I buy shares of BerGenBio ASA?

Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BerGenBio ASA's stock price today?

One share of BRRGF stock can currently be purchased for approximately $1.77.

How can I contact BerGenBio ASA?

BerGenBio ASA's mailing address is Jonas Lies Vei 91, Bergen, Hordaland 5009. The official website for the company is www.bergenbio.com. The company can be reached via phone at 47 53 50 15 64.

This page (OTCMKTS:BRRGF) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -